Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
303 Leser
Artikel bewerten:
(2)

Jenner Law, P.C.: Jenner Law and Alex Davis Law Announce Filing of Landmark Lawsuit Against Cartiva

Finanznachrichten News

Lawsuit Claims Cartiva Knew of Implant Defects and Failed to Warn Patients

BALTIMORE, MD / ACCESSWIRE / December 6, 2024 / Jenner Law, P.C. and Alex Davis Law, PLLC filed a significant products liability lawsuit in the United States District Court for the District of Maryland against Cartiva, Inc., and its associated corporate entities. The lawsuit was filed on behalf of a Maryland resident who suffered severe harm caused by the Cartiva Synthetic Cartilage Implant (SCI).

The complaint alleges that Cartiva marketed and sold a defective toe implant that failed in approximately two-thirds of patients, as documented in recent independent studies. Despite high failure rates and reports of severe complications, Cartiva continued to sell the device until it was recalled on October 31, 2024.

The complaint highlights Cartiva's recall of the Cartiva Synthetic Cartilage Implant (Cartiva SCI), which was prompted by reports of alarmingly high failure rates, including implant shrinkage, loosening, and migration. These issues can lead to severe pain, bone loss, and the need for costly, painful revision surgeries among patients. According to the recall notice, healthcare providers were instructed to remove and quarantine any remaining implants and to monitor patients for new or worsening symptoms. The plaintiff, Robert Connor of Chevy Chase, Maryland, alleges that this recall underscores long-standing concerns about the device's dangerous failure rate and that Cartiva failed to act sooner, despite knowing about the defects and associated risks for years.

"Cartiva failed to live up to its promises and put profits ahead of patient safety," said Robert K. Jenner, founding partner of Jenner Law. "This lawsuit is about holding Cartiva accountable for the pain and suffering they've caused to patients who trusted their product."

The Cartiva SCI, marketed as a minimally invasive alternative to toe fusion for arthritis patients, has been found to degrade quickly, leading to pain, swelling, and the need for revision surgeries. The lawsuit alleges that the defendants failed to provide accurate information to both patients and medical professionals about the risks associated with the device.

Alex Davis, lead attorney from Alex Davis Law, added, "Our client suffered not only from the physical harm caused by this defective implant but also from the emotional and financial toll of revision surgeries and ongoing treatment. Companies like Cartiva must be held accountable for failing to ensure the safety and effectiveness of their products."

The case represents a broader issue in medical device accountability, with claims that Cartiva knowingly withheld adverse event data and failed to address manufacturing defects. Hundreds and perhaps thousands of additional people have suffered similar injuries due to the failure of the Cartiva device. Jenner Law and Alex Davis Law urge anyone affected by the Cartiva SCI to seek legal advice.

About Alex Davis Law

Alex Davis Law, located in Louisville, Kentucky, specializes in representing clients in complex litigation, including defective medical devices and pharmaceutical negligence.

Contact Information

Robert K. Jenner
rjenner@jennerlawfirm.com
410-413-2155

Alex C. Davis
alex@alexdavislaw.com
502-882-6000

William H. Mapes
will@alexdavislaw.com

.

Source: Jenner Law, P.C.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.